<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04748562</url>
  </required_header>
  <id_info>
    <org_study_id>MS 483/2019</org_study_id>
    <nct_id>NCT04748562</nct_id>
  </id_info>
  <brief_title>Vaginal Progesterone 400mg v.s 200mg for Prevention of Preterm Labor in Twin Pregnancies</brief_title>
  <official_title>Vaginal Progesterone 400mg v.s 200mg for Prevention of Preterm Labor in Twin Pregnancies: a Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is already known that the risk of preterm labor in twin pregnancy before 37 week is 8-9&#xD;
      fold higher compared to singletons, and progesterone supplementation can decrease the&#xD;
      incidence of preterm labor in singleton pregnancy.&#xD;
&#xD;
      There were studies that used 200mg vaginal progesterone with no effect on the result So this&#xD;
      study aims To examine the effect of prophylactic vaginal progesterone 400mg v.s 200mg for&#xD;
      prevention of preterm birth in twin pregnancies&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Actual">December 1, 2020</completion_date>
  <primary_completion_date type="Actual">August 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preterm labor</measure>
    <time_frame>Before 37 weeks gestation</time_frame>
    <description>Number of participants which had preterm labor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cervical length changes</measure>
    <time_frame>Between 14 weeks and 22 weeks gestation</time_frame>
    <description>Cervical length changes in centimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal ICU admission</measure>
    <time_frame>The first 28 days after delivery</time_frame>
    <description>Number of neonates required neonatal ICU admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal mechanical ventilation</measure>
    <time_frame>The first 28 days after delivery</time_frame>
    <description>Number of neonates required mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progesterone side effects</measure>
    <time_frame>During one year which is the period from the start of the study till its end</time_frame>
    <description>The number of patients experiencing progesterone side effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Twin Pregnancy With Antenatal Problem</condition>
  <arm_group>
    <arm_group_label>400 mg progesterone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Taking 400 mg vaginal progesterone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg progesterone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Taking 200 mg vaginal progesterone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>Taking prontogest vaginally</description>
    <arm_group_label>200 mg progesterone group</arm_group_label>
    <arm_group_label>400 mg progesterone group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Primigravidae&#xD;
&#xD;
          2. Twin pregnancies at gestational age 14 week.&#xD;
&#xD;
          3. Cervical length more than 2 cm (because if 2cm or less they will undergo cervical&#xD;
             cerclage.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Polyhydramnios&#xD;
&#xD;
          -  Anemia&#xD;
&#xD;
          -  Twins with congenital malformation&#xD;
&#xD;
          -  Twin to twin transfusion&#xD;
&#xD;
          -  Medical diseases as diabetes mellitus, hypertension and systemic lupus erythematosis&#xD;
&#xD;
          -  Previous cervical surgery&#xD;
&#xD;
          -  High order pregnancy (triples or more)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ain Shams University Maternity hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 31, 2021</study_first_submitted>
  <study_first_submitted_qc>February 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Progesterone</keyword>
  <keyword>Twin pregnancy</keyword>
  <keyword>Preterm labor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obstetric Labor, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

